China Pharma Holdings Inc (CPHI)vsZoetis Inc (ZTS)
CPHI
China Pharma Holdings Inc
$0.76
-0.35%
HEALTHCARE · Cap: $32.71M
ZTS
Zoetis Inc
$72.97
+0.15%
HEALTHCARE · Cap: $30.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 243251% more annual revenue ($9.53B vs $3.91M). ZTS leads profitability with a 27.7% profit margin vs -114.3%. CPHI appears more attractively valued with a PEG of 0.16. ZTS earns a higher WallStSmart Score of 58/100 (C).
CPHI
Avoid31
out of 100
Grade: F
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+35.2%
Fair Value
$0.97
Current Price
$0.76
$0.21 discount
Margin of Safety
+11.3%
Fair Value
$145.00
Current Price
$72.97
$72.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -20.9% — below average capital efficiency
Revenue declined 7.5%
Trading at 9.3x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : CPHI
The strongest argument for CPHI centers on PEG Ratio, Price/Book, Debt/Equity. PEG of 0.16 suggests the stock is reasonably priced for its growth.
Bull Case : ZTS
The strongest argument for ZTS centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : CPHI
The primary concerns for CPHI are EPS Growth, Market Cap, Return on Equity.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
CPHI profiles as a turnaround stock while ZTS is a declining play — different risk/reward profiles.
CPHI carries more volatility with a beta of 1.05 — expect wider price swings.
ZTS is growing revenue faster at -0.2% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 31/100), backed by strong 27.7% margins. CPHI offers better value entry with a 35.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
China Pharma Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · China
China Pharma Holdings, Inc. develops, manufactures and markets generic and branded pharmaceutical and biochemical products primarily for hospitals and private retailers in the People's Republic of China. The company is headquartered in Haikou, the People's Republic of China.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?